MedPath

Transvaginal Ultrasound and Photoacoustic Imaging of Ovary

Not Applicable
Recruiting
Conditions
Ovary; Anomaly
Registration Number
NCT04178018
Lead Sponsor
Washington University School of Medicine
Brief Summary

This study is being conducted to validate if photoacoustic imaging potentially reduces benign surgeries without compromising cancer detection sensitivity. The study will also explore whether using the photoacoustic imaging/ultrasound technique has any potential with early ovarian cancer detection in a group of high risk patients.

Detailed Description

In primary and secondary objectives, the investigators will consent patients who are at risk for ovarian cancer, or who have an ovarian mass possibly suggestive of a malignancy and are counseled to undergo oophorectomy. Patients will be identified by the GYN physicians and consented by the study coordinator prior to the date of the scheduled surgical procedure.

In exploratory objectives, the investigators will consent patients who are at risk for ovarian cancer and wish to be followed before making decision to undergo prophylactic oophorectomy. Patients will be identified based on the eligibility criteria by the physicians and consented by the study coordinator prior to the follow up studies.

Recruitment & Eligibility

Status
RECRUITING
Sex
Female
Target Recruitment
310
Inclusion Criteria

Not provided

Exclusion Criteria
  • Male
  • Younger than 18 years of age

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Assess the impact of co-registered PAI/US on the potential reduction of benign surgeries as measured by the area under receiver characteristic curve (AUC)At the time of surgery (estimated to be 2 weeks)

The anticipated improvement of diagnostic accuracy on reduction of surgeries of benign ovaries will be from current practice of AUC=55% to AUC=78%.

Secondary Outcome Measures
NameTimeMethod
False negative rate of conventional imaging compared to conventional imaging & PAI/US as measured by sensitivity of cancer detectionAt the time of surgery (estimated to be 2 weeks)

The anticipated improvement of cancer detection accuracy will be from current practice of 80% to 94%.

Trial Locations

Locations (1)

Washington University School of Medicine

🇺🇸

Saint Louis, Missouri, United States

Washington University School of Medicine
🇺🇸Saint Louis, Missouri, United States
Cary L Siegel, M.D.
Principal Investigator
Matthew Powell, M.D.
Sub Investigator
Andrea Hagemann, M.D.
Sub Investigator
William Middleton, M.D.
Sub Investigator
David Mutch, M.D.
Sub Investigator
Malak Itani, M.D.
Sub Investigator
Anup Shetty, M.D.
Sub Investigator
Valerie Ratts, M.D.
Sub Investigator
Lindsay K Kuroki, M.D.
Sub Investigator
Carolyn McCourt, M.D.
Sub Investigator
Katherine Fuh, M.D., Ph.D.
Sub Investigator
Ian S Hagemann, M.D., Ph.D.
Sub Investigator
Esther Lu, Ph.D.
Sub Investigator
Quing Zhu, Ph.D.
Sub Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.